<DOC>
	<DOCNO>NCT00537030</DOCNO>
	<brief_summary>This clinical trial study side effect Erwinia asparaginase happen drug body treat young patient acute lymphoblastic leukemia allergic PEG-asparaginase . Drugs use chemotherapy , Erwinia asparaginase , work different way stop growth cancer cell , either kill cell stop dividing .</brief_summary>
	<brief_title>Erwinia Asparaginase After Allergy PEG-Asparaginase Treating Young Patients With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>Primary Aims 1 . To determine 48 hour trough serum asparaginase activity ≥0.1 IU/mL . 2 . To determine frequency asparaginase-related toxicity follow Erwinase® treatment . 3 . To characterize pharmacokinetics Erwinase child leukemia allergy PEG-asparaginase . Secondary 1 . To informally compare serum asparaginase activity plasma asparagine concentration patient treat Erwinase® trial historical control treat PEG-asparaginase CCG-1962 1961 . 2 . To determine 72 hour serum asparaginase activity ( Day 8 ( pre-dose 4 ) course Erwinase® start Monday ; Day 13 ( pre-dose 6 ) course Erwinase® start Wednesday ; Day 11 ( pre-dose 5 ) course Erwinase® start Friday ) . 3 . To determine presence anti-Erwinia asparaginase antibody child treat course ( ) Erwinase® follow clinical allergy PEG -asparaginase ( PEG , pegaspargase ) . 4 . To determine plasma asparagine adequately deplete ( Day 12 ( pre-dose 6 ) course Erwinase® start Monday ; Day 13 ( pre-dose 6 ) course Erwinase® start Wednesday Friday ) subset patient . Patients receive 6 dos Erwinia asparaginase intramuscularly ( IM ) Monday/Wednesday/Friday schedule replacement schedule dose PEG-asparaginase remain original treatment protocol . All chemotherapy continue accord original treatment protocol . Blood sample collect periodically pharmacokinetic , pharmacodynamic , antibody study . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>Diagnosis acute lymphoblastic leukemia Concurrently enrol frontline Children 's Oncology Group treatment trial ( i.e. , COGAALL0232 COGAALL0531 , COGAALL0331 , COGAALL0434 ) participate institution Must 1 course asparaginase remain administered treatment protocol Must grade ≥ 2 hypersensitivity reaction PEGasparaginase No history pancreatitis ≥ grade 2 No prior Erwinia asparaginase</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>